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Original Article 
TNF Receptor-Associated Factor 4 (TRAF4) is a novel binding partner of glycoprotein 
Ib and glycoprotein VI in human platelets 
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SUMMARY 
Background: Reactive oxygen species generation is one consequence of ligand engagement of 
platelet glycoprotein (GP) receptors GPIb-IX-V and GPVI, which bind VWF/collagen and 
initiate thrombosis at arterial shear, however the precise molecular mechanism coupling redox 
pathway activation to engagement of these receptors is unknown. Objective: The objective of 
this study was to identify novel binding partners for GPIb-IX-V and GPVI that could provide 
a potential link between redox pathways and early platelet signalling events. Methods and 
Results: Using protein array analysis and affinity-binding assays, we demonstrated that the 
orphan TNF receptor-associated factor (TRAF) family member, TRAF4, selectively binds 
cytoplasmic sequences of GPIbβ and GPVI. TRAF4, p47phox (of the NADPH oxidase (Nox2) 
enzyme complex), and other redox relevant signalling proteins such as Hic-5, co-
immunoprecipitate with GPIb/GPVI from human platelet lysates whilst MBP-TRAF4 or 
MBP-p47phox fusion proteins specifically pull-down GPIb/GPVI. GPIb- or GPVI-selective 
agonists induce phosphorylation of the TRAF4-associated proteins, Hic-5 and Pyk2, with 
phosphorylation attenuated by Nox2 inhibition. Conclusion: These results describe the first 
direct association of TRAF4 with a receptor, and identify a novel binding partner for GPIb-
IX-V and GPVI, providing a potential link between these platelet receptors and downstream 
TRAF4/Nox2-dependent redox pathways. 
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INTRODUCTION 
The initial adhesion of platelets to exposed vascular matrix at arterial and pathological shear 
rates is dependent on two unique platelet receptors, glycoprotein (GP)VI, which binds 
collagen, and GPIb-IX-V, which binds von Willebrand Factor (VWF) and other ligands 
(reviewed in [1, 2]). GPIb-IX-V and GPVI play a central role in initiating thrombotic diseases 
such as myocardial infarction or stroke and are implicated in platelet dysfunction associated 
with bleeding disorders, coagulopathy, immune and non-immune thrombocytopenias, and 
inflammatory arthritis [3-6] (and references therein). Important roles for these receptors are 
also emerging in experimental animal models of metastasis [7-9]. Understanding how 
engagement of these receptors initiates signalling events leading to activation of the platelet 
integrin, αIIbβ3, which binds fibrinogen or VWF to mediate platelet aggregation, should 
provide new avenues for clinical diagnosis or treatment.  
In complex with the Fc receptor γ-chain (FcRγ) dimer, GPVI is the major collagen 
signalling receptor on platelets. Engagement of GPVI activates intracellular signalling events 
leading to platelet aggregation through αIIbβ3, and to activation of the collagen-binding 
integrin, α2β1, which stabilizes the interaction of platelets with fibrillar collagen [2]. The 51 
amino acid cytoplasmic tail of GPVI interacts with constitutively-bound Src family kinases, 
Fyn and Lyn [10, 11], and calmodulin [12]. When GPVI is cross-linked by binding collagen, 
a GPVI-specific activating collagen-related peptide (CRP), or snake venom-derived GPVI 
agonists such as convulxin, GPVI forms a disulfide-dependent homodimer [13] and 
constitutively-bound Src kinases phosphorylate the immunoreceptor tyrosine-based activation 
motif (ITAM) sequence in FcRγ, allowing the assemblage of Syk and activation of 
downstream signalling pathways [10]. 
GPVI is physically and functionally associated, at least in part [14], with the GPIb-IX-V 
complex consisting of GPIbα (the major ligand-binding subunit) disulfide-linked to GPIbβ 
  
and noncovalently associated with GPIX and GPV [1]. The cytoplasmic tail of GPIb-IX-V 
includes binding sites for actin-binding filamin, 14-3-3ζ,  calmodulin and the p85 regulatory 
subunit of phosphoinositide 3-kinase (PI3-kinase) [15-17]. Studies using pharmacological 
inhibitors or genetically-modified mice deficient in individual signalling proteins have 
defined early signalling events upstream of a secretion-dependent pathway. The most 
receptor-proximal signalling protein identified is Lyn, which is upstream of Syk, SLP-76, 
Bruton tyrosine kinase (Btk), PI3-kinase and PLCγ2, leading sequentially to release of 
agonists such as ADP and TXA2, which activate platelets in an autocrine fashion and facilitate 
activation of  αIIbβ3 [18]. A second secretion-independent pathway involving NO/cGMP/PKG 
upstream of p38 and ERK1/2, also leading to αIIbβ3 integrin activation, has been proposed 
[19]. Lyn is also the first identified signalling protein in this pathway [20], upstream of PI3-
kinase and Akt [17, 20]. Other workers have also identified key signalling proteins activated 
downstream of GPVI in human or mouse platelets, including PI3-kinase, Akt and other 
members of Lyn/Syk-initiated pathways [21-24]. 
Despite these considerable research efforts, the molecular mechanism by which GPVI- 
and GPIb-IX-V-associated proteins coordinate the assemblage and activation of Lyn-
dependent signalling pathways in human platelets is not understood and roles for additional 
receptor-associated proteins are feasible. In this study, we used protein-array and affinity-
binding approaches to search for new binding partners for the cytoplasmic tails of GPIb-IX-V 
and GPVI and identified tumor necrosis factor (TNF) receptor-associated factor (TRAF) 
family member, TRAF4, as a novel binding partner for both receptors. Both GPIb-IX-V and 
GPVI interacted with TRAF4 as well as TRAF4-associated proteins Hic-5, p47phox and Pyk2. 
These interactions were functional since TRAF4-associated proteins, Hic-5 and Pyk2, could 
be phosphorylated by selective ligand binding at either GPIb-IX-V or GPVI. Our findings 
help illustrate how platelet receptor-ligand interactions integrate with Lyn-dependent 
  
signalling pathways and provide the first evidence of association of TRAF4 with mammalian 
receptors, thus characterising a redox-relevant molecular pathway linking GPIb-IX-V and 
GPVI activation to reactive oxygen species (ROS)-dependent regulation of platelet function. 
 
MATERIALS AND METHODS 
Antibodies  
Anti-p47phox, anti-TRAF4, anti-Hic-5, anti-Lyn and anti-Pyk2 monoclonal antibodies were 
from BD Biosciences (San Jose, CA); anti-Hic-5 polyclonal antibody from Cell Signaling 
Technology (Boston, MA); anti-phosphotyrosine (4G10) and anti-Syk monoclonal and anti-
Pyk2 polyclonal antibodies from Millipore (Upstate; CA, USA); and anti-phosphotyrosine 
(PY20) was from Zymed Laboratories (San Francisco; CA). Anti-GPVI ectodomain, anti-
glycocalicin (GPIbα ectodomain) and anti-GPIbβ tail polyclonal antibodies, and anti-αIIb 
(CRC54) and anti-GPVI (6B12, 4B8, 12A5) monoclonal antibodies have been previously 
described [5, 14, 25]. HRP-conjugated anti-mouse or anti-rabbit IgG raised in sheep were 
from Chemicon (Melbourne, Australia).  
GPVI- and GPIb-specific reagents 
The GPVI-specific agonist, collagen-related peptide (CRP) was generated as previously 
described [26]. COS-7 cells expressing the VWF-A1 domain containing an R543W mutation 
(a gain-of-function mutation found in Type 2B von Willebrand’s disease) were used as a 
selective agonist for GPIb-IX-V [27]. This agonist robustly activates platelets without the 
requirement for modulators, and a ratio of 1:1200 COS-7 cells:platelets was used in the 
present study.  
Screening of protein array 
To identify proteins that specifically bind to the membrane-proximal cytoplasmic sequence of 
GPIbβ (Arg151–Ala161), a hEx1 human recombinant protein array on PVDF membrane (222 
  
x 222 mm, Millipore) was screened with a biotin-RRLRARARARA peptide, as previously 
described [28]. The high density protein array is comprised of proteins expressed from cDNA 
clones from the hEx1 library, a human foetal brain cDNA library subcloned into an E. coli 
strain SCS-1, which permits IPTG-inducible expression of His6-tagged fusion proteins 
directly onto a membrane. The polyvinylidene difluoride (PVDF) array contained up to 
28,000 spots in duplicate in a distinct 5 x 5 pattern around a guide dot. Bound peptide was 
detected using an anti-biotin antibody (Amersham Biosciences, Sweden). The identity of 
positive clones was determined by sequencing and BLAST analysis. 
MBP-GPIbβ and MBP-GPVI affinity columns  
A maltose-binding protein (MBP)-GPVI cytoplasmic tail (Glu266–Ser316) fusion protein was 
prepared as previously described [10]. MBP-GPIbβ cytoplasmic tail (Arg149–Ser181) was 
prepared using similar methods. Proteins (~0.1 mg) were coupled to a 1:1 mixture of Affigel-
10/15 resin (Bio-Rad, Richmond, CA; ~10-mL bed volume) using published methods [29]. 
Detergent-free human platelet lysates were prepared as previously described [30], then 
separated on MBP-GPIbβ or MBP-GPVI affinity columns. Flow-through or guanidine-HCl 
eluted fractions (1 mL) were dotted onto nitrocellulose membranes and immunoblotted for 
specific signalling proteins. 
MBP-TRAF4 MATH domain and MBP-p47phox SH3 domain fusion proteins 
Human TRAF4 cDNA and human p47phox cDNA were purchased from OriGene (Rockville, 
MD). The cDNA corresponding to TRAF4-MATH (meprin and traf homology) domain 
(amino acid sequence 307-462) cDNA was synthesized by PCR with a BamHI overhang 
forward primer (5’CGC GGA TCC GAT GGC GTG CTC ATC TGG AAG ATT G 3’) and 
HindIII overhang reverse primer (5’ CCC AAG CTT TCA AAC AGC AGC ACG GAT GAA 
GAC TGC ATC). Human p47phox cDNA corresponding to tandem SH3 domains (amino acid 
sequence 151-292) was synthesized by PCR with an EcoRI overhang forward primer (CCG 
  
GAA TCC GAC ATC ACC GGA CCC ATC ATC CAG) and SalI overhang reverse primer 
(ACGC GTC GAC TCA GCG TTG GGC CTG GGA CAC).  PCR products of TRAF4-
MATH domain and p47phox-SH3 domains were digested with the corresponding restriction 
enzymes and cloned into pMAL-C2X vector (New England BioLabs, MA). Both TRAF4-
MATH and p47phox-SH3 constructs were verified by sequencing. 
MBP-TRAF4-MATH domain fusion protein and MBP-p47phox-SH3 domain fusion 
protein were expressed in E.coli BL-21(DE3) with 1 mM IPTG induction at 37oC for 3 h. 
MBP-p47phox-SH3 was purified according to the manufacturer’s instruction (New England 
BioLabs). Since MBP-TRAF4-MATH was insoluble, transfected E.coli cells were 
resuspended in column buffer (20 mmol/L Tris-HCl, 200 mmol/L NaCl, 1 mmol/L EDTA, pH 
7.4) containing 1 mg/mL lysozyme and Complete protease inhibitor cocktail and rocked at 
room temperature for 15 min. The lysate was made 0.25% (v/v) sarcosyl detergent and 
sonicated. Insoluble material was pelleted by centrifugation (16,000g; 30 min; 4oC) and 
supernatant made 1% (v/v) Triton X-100 and loaded onto amylose resin (New England 
BioLabs). Bound protein was eluted with column buffer containing 10 mmol/L maltose, 0.1% 
(v/v) sarcosyl and 0.5% (v/v) Triton X-100, and dialysed into TS buffer (10 mmol/L Tris, 150 
mmol/L NaCl, pH.7.4) containing 0.08% (v/v) sarcosyl. 
GPIb- and GPVI-dependent platelet activation 
Human platelets were isolated from venous blood using acid citrate dextrose as the 
anticoagulant, washed and resuspended at 5 x 108/mL as previously described [16]. Platelet 
aggregation was induced by addition of (final concentrations) CRP (2.5–10 μg/mL) or VWF-
A1/R543W cells (cell-to-platelet ratio of 1:1200), with stirring at 900 rpm in a 
Lumiaggregometer (Chronolog, Havertown, PA) at 37oC.  In some experiments, platelets 
were preincubated with the Nox inhibitor apocynin (100 μmol/L; Calbiochem, San Diego) or 
redox inhibitors quercetin (100 μmol/L; Sigma) or diphenylene iodonium (DPI, 10 μmol/L; 
  
Sigma) for 10 min prior to adding agonist. In other experiments, platelets were pre-treated 
with an RGD-containing peptide (GRGDSP; Auspep, Melbourne, Australia) at 1 mmol/L 
final concentration to inhibit ligand binding to αIIbβ3 and αIIbβ3-dependent platelet 
aggregation. Bands corresponding to GPVI homodimer were scanned and optical density 
(O.D.) quantified using ImageJ software (NIH, Bethesda, MA; http://rsb.info.nih.gov/ij/). 
Data were expressed as mean O.D ± SEM and statistical difference was calculated using a 
one-way ANOVA with Newman-Keuls post-hoc test. 
Immunoprecipitation and MBP-fusion protein pull-down assay 
Immunoprecipitation from Triton-soluble supernatants was performed by addition of 4–10 μg 
antibody to pre-cleared platelet lysates and incubation overnight at 4oC [14]. For 
immunoprecipitations involving TRAF4 and Pyk2, the lysis buffer also contained 10 mmol/L 
N-ethylmaleimide to dissociate GPIb from the cytoskeleton [14, 17], ensuring that association 
with GPIb was not due to mutual cytoskeletal attachment.  Protein G sepharose was used in 
TRAF4 immunoprecipitations due to a non-specific band of a similar molecular weight to 
TRAF4 in protein A sepharose immunoprecipitations. Platelet lysates were also precipitated 
with MBP-TRAF4-MATH or MBP-p47phox-SH3 (20–40 μg/mL). Immunoprecipitates and 
pull-downs were resolved by SDS-5–20% polyacrylamide gel and immunoblotted as 
described elsewhere [12, 17]. Blots were visualized using HRP-conjugated secondary 
antibodies and enhanced chemiluminescence (Amersham, Buckinghamshire, UK).  
 
RESULTS 
Identification of novel binding partners of GPIbβ and GPVI 
We previously showed that calmodulin dynamically interacts with analogous membrane-
proximal positively-charged intracellular sequences of GPIbβ (RRLRARARARA) and GPVI 
(KRLRHRGRAVQ) [12, 16]. To investigate whether other proteins could interact with these 
  
sequences (potentially regulated by calmodulin binding), a protein array displaying 28,000 
recombinant, human proteins was probed with the GPIbβ-based peptide (biotin-
RRLRARARARA). This screen identified the assemblage and signalling protein, TRAF4, as 
one of two potential GPIbβ-binding proteins. To confirm the protein array data, a 100,000g 
non-detergent lysate of platelets was chromatographed on an MBP-GPIbβ cytoplasmic tail 
affinity column and bound proteins were eluted with guanidinium-HCl. TRAF4 was detected 
in the eluted fractions, supporting an association with GPIbβ (Figure 1). An MBP-GPVI 
cytoplasmic tail affinity column also bound TRAF4 (Supplementary Figure 1). 
GPIb and GPVI associate with TRAF4, p47phox, Hic-5 and Pyk2 in human platelet 
lysates 
TRAF4 does not bind to TNF receptors [31] and has not been definitively linked to any other 
receptor type. In endothelial cells, TRAF4 localises NADPH oxidase (Nox2)-derived ROS 
generation to specific subcellular regions through its independent binding partners, Hic-5, and 
the Nox2 subunit, p47phox [32]. To ascertain whether a TRAF4/Hic-5/p47phox complex is 
associated with GPIb-IX-V and GPVI in platelets, GPVI and GPIb were immunoprecipitated 
from Triton X-100-soluble platelet lysates and probed for TRAF4, Hic-5 and p47phox. Both 
anti-GPIb and anti-GPVI antibodies, but not a control polyclonal antibody, 
immunoprecipitated TRAF4, p47phox and Hic-5 (Figure 2A). The association of p47phox with 
GPVI was less marked than that with GPIb, possibly reflecting an indirect association of 
GPVI and p47phox through co-association with GPIb [14]. Hic-5 in platelets is physically and 
functionally associated with proline-rich tyrosine kinase, Pyk2 [33], and is constitutively 
bound to the Src family kinase Lyn [34], both of which also co-immunoprecipitate with GPIb 
and GPVI (Figure 2B and 2C, upper panels). To confirm that any observed differences in co-
immunoprecipitation were not due to reduced immunoprecipitation of GPIb or GPVI, 
immunoblots were reprobed with anti-GPIb and anti-GPVI monoclonal antibodies (Figure 2B 
  
and 2C, lower panels). Immunoprecipitation conditions and antibodies were consistent for all 
co-immunoprecipitations and the levels of GPVI and GPIb were similar for all immunoblots. 
GPVI and GPIb associate with the MATH domain of TRAF4 and SH3 domains of 
p47phox 
TRAF4 (54 kDa) is comprised of a zinc finger domain, three consecutive traf-like zinc finger 
domains, a coiled-coil region and a meprin and traf homology (MATH) domain [31] that is 
required for the interaction of other TRAF-family members with receptors [35]. The core 
region of p47phox containing tandem SH3 domains is critical for the assembly and activation of 
Nox2 [36]. To further characterise the association of TRAF4 and p47phox with GPVI and 
GPIb, MBP-fusion proteins containing the MATH domain of TRAF4 (residues 307–462) or 
the SH3 domains of p47phox were used in platelet lysate pull-down assays. Both MBP-
TRAF4-MATH and MBP-p47phox-SH3, but not a control fusion protein (MBP-LacZ) or 
amylose resin alone, pulled down GPVI and GPIb but not αIIbβ3 from platelet lysates (Figure 
3A). The TRAF4-associated protein, Hic-5, was also pulled down by MBP-TRAF4-MATH 
and MBP-p47phox-SH3. Pyk2 was pulled down using MBP-TRAF-MATH, as well as fusion 
proteins containing the cytoplasmic tail portions of GPVI and GPIbβ (Figure 3B). Together 
with the immunoprecipitation data, these experiments confirm the association of a 
TRAF4/Hic-5/p47phox complex with the cytoplasmic tails of GPIb and GPVI.  
 
Redox-sensitive phosphorylation of Hic-5 and Pyk2 following treatment of platelets with 
GPIb- and GPVI-dependent agonists 
In endothelial cells, TRAF4, Hic-5 and Pyk2 have a strong physical and functional 
association in focal adhesions [32]. Localised ROS, particularly H2O2, modulate cell 
migration via oxidative inactivation of focal complex-targeted protein tyrosine phosphatases 
such as PTP-PEST [37], which binds Hic-5 [38] and is a negative regulator of Pyk2 [39] and 
  
Hic-5 [40].  Hic-5 has previously been reported to be physically and functionally associated 
with Pyk2 in platelets [33], and Pyk2 is rapidly tyrosine phosphorylated following ligand 
binding to GPIb-IX-V [41]. To ascertain whether the platelet receptor-associated TRAF4/Hic-
5/p47phox complex is functional, tyrosine-phosphorylated proteins were immunoprecipitated 
from platelet lysates after treatment with VWF-A1/R543W COS-7 cells (GPIbα-specific 
agonist) or CRP (GPVI-specific agonist) and levels of Hic-5 and Pyk2 assessed by 
immunoblotting. A transient phosphorylation of Pyk2 (Figure 4A) and Hic-5 (Figure 4B), 
peaking between 1 and 5 min, was detected after treatment with either ligand. Early tyrosine 
phosphorylation of Hic-5 and Pyk2 was unaffected in platelets pre-treated with an RGD-
containing peptide to prevent integrin engagement (data not shown), indicating that signalling 
through αIIbβ3 did not contribute to Hic-5/Pyk2 phosphorylation, consistent with other reports 
[41, 42]. The phosphorylation was redox-sensitive as pre-incubation of platelets with the cell-
permeable Nox inhibitor apocynin significantly reduced CRP- (Figure 5) or VWF-
A1/R543W-induced (data not shown) tyrosine phosphorylation of Hic-5 (Figure 5A) and 
Pyk2 (Figure 5B). These data demonstrate that intracellular proteins important for the 
generation of ROS are co-associated with platelet signalling receptors and that ligation of 
either GPVI or GPIb triggers phosphorylation of Pyk2 and Hic-5, components of the Nox2 
signalling pathway.  
To further demonstrate a role for redox in platelet signalling/activation leading to 
platelet aggregation, we investigated the effect of Nox2 inhibition on platelet aggregation 
induced by GPVI- or GPIb-specific agonists. Treatment of platelets with increasing 
concentrations of apocynin inhibited the aggregation of platelets induced by CRP (Figure 6A) 
or VWF-A1/R543W cells (data not shown). We also examined the effect of Nox2 inhibition 
on GPVI dimer formation induced by CRP in the presence of the metalloproteinase inhibitor 
GM6001, which maintains the dimer on the platelet surface [13]. Dimer formation is 
  
independent of Src family-dependent GPVI signalling, and indicates the generation of a rapid 
transient oxidative submembranous environment in activated platelets. Inhibition of Nox2 
with apocynin consistently impaired CRP-induced dimer formation (optical density at 10 min: 
0.39±0.15 cf 0.86±0.14 in the presence and absence of apocynin, respectively; p<0.01; n=3 
independent experiments using different donors; Figure 6B).  These data indicate that 
inhibition of Nox2 impairs GPVI dimer formation, which precedes downstream signalling. 
Similarly, in GPVI immunoprecipitates of CRP-treated platelets, pretreatment with apocynin 
or another redox inhibitor, diphenylene iodonium (DPI), prevented the CRP-induced 
dissociation of calmodulin from GPVI, implying that activation of the Nox2 signalling 
pathway precedes this early event (within 1 min; Figure 6C, upper panel) as well as the 
subsequent cleavage of GPVI, which occurs within 3 min (Figure 6C, lower panel). Further, 
while calmodulin is dissociated from GPVI following CRP treatment, TRAF4 could still be 
co-immunoprecipitated (Figure 6D). Taken together, these data indicate a role for intracellular 
platelet-derived ROS in GPVI- and GPIb-dependent platelet activation and point to a key role 
for Nox2 in regulating GPIb-IX-V/GPVI-dependent platelet aggregation at elevated shear 
rates. 
 
DISCUSSION 
Platelet adhesion at sites of atherosclerotic plaque rupture, mediated primarily though the 
platelet receptors, GPIb-IX-V and GPVI, is an initiating factor in cardiovascular disease. 
Reactive oxygen species (ROS) such as superoxide anion (O2.-) and hydrogen peroxide 
(H2O2) are also strongly linked to the pathogenesis of cardiovascular disease [43], however 
the precise mechanisms for how redox changes regulate, or are regulated by, platelet adhesion 
receptors are not well understood. Here we present evidence that key molecular players, 
  
TRAF4, Hic-5, p47phox and Pyk2, central to functional redox pathways in other cell types, are 
physically, functionally and constitutively associated with platelet GPIb-IX-V and GPVI. 
Members of the tumor necrosis factor-associated factor (TRAF) family function as 
adaptors in receptor-mediated signalling in several pathways and interact with TNF receptors 
and interleukin-1/toll-like receptor (IL-1R/TLR) family members. TRAF4 is distinctive in 
that it does not possess the conserved residues necessary for recognition by TNF receptors, 
and only weak interactions under certain conditions have been reported [44]. TRAF4 has 
therefore been suggested to interact with alternative transmembrane proteins [31], but the 
identity of these putative TRAF4-binding receptors is unknown. Several intracellular binding 
partners for TRAF4 have been identified, beginning with the p47phox subunit of the 
superoxide-generating enzyme complex NADPH oxidase (Nox2) [45]. Nox2 is a multi-
subunit protein comprising two membrane-bound subunits: gp91phox (Nox2) and p22phox, three 
cytoplasmic subunits: p47phox, p40phox, p67phox, and a small GTP-binding protein Rac1/2 [46]. 
TRAF4 and p47phox localise subcellular production of ROS during endothelial cell migration 
through interaction with further TRAF4-binding partners, the focal adhesion scaffold protein 
Hic-5 and the redox-sensitive tyrosine kinase Pyk2 [32]. This localised activation of Nox2 is 
one of the key mechanisms for regulating Lyn as well as controlling other cellular functions 
such as lamellipodia formation and cell motility [32, 47]. 
Lyn is pivotal in mediating early GPVI- and GPIb-dependent signalling events in 
platelets [2, 48] and thus its activation and regulation must be tightly regulated. While 
signalling pathways downstream of Lyn have been delineated, how receptor-associated 
proteins integrate their assemblage and activation of these Lyn-dependent signalling pathways 
is still unknown. Work presented here localises molecular components of pathways known to 
mediate intracellular redox, to the cytoplasmic tails of GPIb or GPVI (Figure 7). We and 
others have shown association of Lyn and the downstream tyrosine kinase Syk with GPIb and 
  
GPVI [10, 48]. Further, Lyn is constitutively bound via its SH3 domain to the TRAF4-
binding partner Hic-5 [34]. Our data therefore demonstrate that many of the proteins involved 
in the redox signalling pathway are preassembled on GPIb and GPVI enabling rapid signal 
transduction in response to receptor ligation. A recent study reports that GPVI-bound Lyn is 
maintained in an active state in platelets under resting and stimulated conditions [11], 
however how Lyn is initially activated or becomes activated downstream of GPIb is still 
unclear. 
In recent years, numerous receptors on cell types involved in innate immune and 
inflammatory responses have been reported to signal through Nox via the production of ROS, 
and increasing evidence suggests that both platelet GPIb-IX-V and GPVI are redox-regulated. 
Krotz et al [49] reported that the GPVI agonist collagen, but not other agonists such as 
thrombin or ADP, increased Nox-mediated production of O2.-, while scavenging O2.- with 
superoxide dismutase (SOD) attenuated secondary phases of aggregation, and exogenous O2.- 
increased ADP release from collagen-stimulated platelets. H2O2 has for many years been 
implicated in platelet signalling pathways initiated by collagen but not thrombin or ADP [50, 
51]. Thrombus formation on collagen under high shear (1000 s-1), dependent on GPIb-IX-
V/GPVI binding, was blocked by the generic Nox inhibitors, diphenylene iodonium (DPI) and 
apocynin [52, 53]. Interestingly, platelet secretion and shape change were not affected, 
suggesting a distinct role for O2.- production in activation of αIIbβ3. 
A potential role for TRAF4 in platelet redox signalling (Figure 7) can be inferred from 
endothelial cell work, where the targeting of Nox2 to focal complexes is mediated through a 
TRAF4/Hic-5/p47phox complex. This stimulates localised ROS production that inhibits the 
Hic-5 bound protein tyrosine phosphatase, PTP-PEST, by oxidation of the active site cysteine 
[38], allowing activation of Hic-5-associated Lyn and Pyk2 [34, 47]. Activated Pyk2 leads to 
activation of the Nox2-associated small GTPase, Rac-1/2, by Vav and potentially other 
  
signalling intermediates [47, 54], and activated Rac-1/2 binds and activates PAK-1, which can 
phosphorylate p47phox on multiple serine residues, leading to enhanced Nox2 activity and a 
positive feedback loop increasing ROS generation [32, 47]. Activated Rac-1/2 regulates 
lamellipodia formation [55], and further, the Rac-1/2–PAK-1 complex can activate guanylyl 
cyclase in a non-kinase-dependent process to increase cGMP levels (in platelets an additional 
potential mechanism for elevating cGMP levels) [56]. ROS can also regulate tyrosine 
phosphorylation-dependent signalling via the reversible inactivation of protein tyrosine 
phosphatases (PTPs) [37]. Based on previous studies [47], PTP-PEST is predicted to bind 
Hic-5, although it is possible in platelets that this role is served by a different protein tyrosine 
phosphatase such as Shp-1 or Shp-2. 
Because GPVI and GPIb-IX-V are important for the initiation of platelet aggregation 
at high shear rates, modulation of their downstream signalling could prevent thrombosis 
rather than affecting normal haemostasis. Indirect evidence suggests that therapeutic targeting 
of the interaction between GPIb or GPVI with TRAF4 has the potential to modulate rather 
than abolish platelet function, thereby reducing the risk of major bleeding. Using mutant 
GPVI receptors expressed in a rat basophilic leukaemia (RBL) cell line, Locke et al. [57] 
demonstrated that mutation of half the basic residues in the calmodulin-binding domain of 
GPVI resulted in a lag in the time required for initiation of calcium signalling following 
convulxin stimulation of the cells. While mutating all of the basic residues in the calmodulin-
binding domain disrupted the GPVI/calmodulin interaction and significantly impaired the 
downstream calcium signalling, mutation of only half the residues did not prevent calmodulin 
binding. The loss of signalling associated with these mutations was therefore likely to be due 
to loss of a then-unidentified protein. Of significance, the mutations were generated in the 
TRAF4-binding region of the GPVI cytoplasmic domain, possibly causing disruption of 
TRAF4/receptor interaction and providing a potential explanation for the observed reduction 
  
in receptor signalling. TRAF4 and calmodulin can bind independently to GPVI, since under 
conditions where calmodulin is dissociated from GPVI in CRP-stimulated platelets in the 
current study, TRAF4 is still co-immunoprecipitated with GPVI, indicating that binding of 
TRAF4 to GPVI does not require the presence of calmodulin. 
 TRAF4 knockout mice display different phenotypes with variable penetrance, 
dependent on their genetic background [58, 59]. Mice generated in a mixed 129/SvJ x 
C57BL/6 background exhibit a developmental defect of the upper respiratory tract resulting in 
respiratory abnormalities and pulmonary inflammation [58]. In a pure 129/SvJ genetic 
background, TRAF4 deficiency not only results in a tracheal defect but also in embryonic 
lethality and severe changes in the development of the axial skeleton (a high incidence of 
spina bifida) and the nervous system [59]. The question of platelet function in TRAF4 mice 
has not been addressed, and is likely to be compromised by proinflammatory abnormalities in 
these animals, however no overt bleeding has been reported. Interestingly, although unlike 
other TRAF family members the role of TRAF4 in the immune system is unknown, immune 
function in TRAF4-deficient animals is not impaired. Immune cell development, ROS 
production and phagocytic capacity of neutrophils in these mice was unaffected by the 
absence of TRAF4, whereas migration of dendritic cells was reduced, indicating that the role 
of TRAF4 in ROS generation is more likely to be in a signalling capacity rather than a high 
output, antimicrobial defence mechanism. 
In conclusion, the present study reveals that TRAF4, a binding partner of the 
regulatory subunit of Nox, p47phox, is physically coupled to platelet receptors, GPIb-IX-V and 
GPVI. This novel interaction is potentially responsible for linking these receptors to redox 
signalling pathways. Further studies will need to be undertaken to determine the functional 
consequences of disrupting the TRAF4 association and whether this interaction can be 
targeted therapeutically. 
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FIGURE LEGENDS 
Figure 1. Interaction partners of the MBP-GPIbβ affinity column. 2 μl of each flow-
through or guanidine-HCl eluted fraction were blotted onto a nitrocellulose membrane and 
probed for the following proteins: MBP, GPIbβ, TRAF4, Hic-5, p47phox and Fyb. 
Figure 2. Co-immunoprecipitation of GPVI and GPIb with TRAF4, p47phox and Hic-5. 
Human washed platelets were immunoprecipitated with polyclonal antibodies directed against 
GPVI (anti-GPVI) or GPIb (anti-glyc.) or with a control polyclonal antibody (Cont.). (A) 
Immunoblots were probed with antibodies against TRAF4, p47phox and Hic-5 and visualized 
using an HRP-conjugated secondary antibody and enhanced chemiluminescence.  (B) 
Immunoblots were probed with anti-Pyk2 polyclonal antibody (upper panel) and reprobed 
with anti-GPVI and anti-GPIb monoclonal antibodies (lower panel). (C) Immunoblots were 
probed with anti-Lyn monoclonal antibody (upper panel), then reprobed simultaneously with 
anti-GPVI and anti-GPIb monoclonal antibodies (lower panel). Data are representative of at 
least three independent experiments. Vertical line indicates a repositioned gel lane. In the case 
of (C), 100 μl platelet lysate load was substituted for the 20 μl load seen in the Lyn blot 
above, to allow visualisation of GPVI in the lysate.  P.L., platelet lysate; WB, western blot. 
Figure 3.  Pull-down of GPVI and GPIb by MBP-p47phox-SH3 and MBP-TRAF4-MATH. 
(A) MBP-TRAF4-MATH and MBP-p47phox-SH3 specifically pull down GPIb, GPVI and Hic-
5 from human platelet lysates MBP-LacZ and amylose-resin are negative controls; platelet 
integrin αIIb was not pulled down as a further control. (B) MBP-GPIbβ cytoplasmic tail, 
MBP-GPVI cytoplasmic tail, or MBP-TRAF4-MATH were used to pull down Pyk2 from 
platelet lysates. P.L., platelet lysate; WB, western blot. 
  
Figure 4. Phosphorylation of Hic-5 and Pyk2 following platelet activation. Washed 
platelets were treated with the GPVI agonist CRP (upper panel) or the GPIb agonist VWF-
A1/R543W (lower panel) in the aggregometer for up to 5 min, then lysed and 
immunoprecipitated with a combination of anti-phosphotyrosine antibodies, 4G10 and PY20. 
Immunoblots were sequentially probed for (A) Hic-5 and (B) Pyk2. Data are representative of 
three independent experiments using different donors. NT, no treatment; P.L., platelet lysate; 
PTyr, anti-phosphotyrosine antibodies. 
Figure 5. Inhibition of GPVI-dependent Hic-5 and Pyk2 phosphorylation by Nox 
inhibitor apocynin. Human washed platelets were treated with CRP for 5 min, in the 
presence or absence of 100 μM apocynin, then lysed and immunoprecipitated with a 
combination of anti-phosphotyrosine antibodies, 4G10 and PY20. Immunoblots were 
sequentially probed for (A) Hic-5 and (B) Pyk2. Data are representative of 3 independent 
experiments using different donors. NT, no treatment; P.L., platelet lysate; Cont., irrelevant 
monoclonal antibody; PTyr, anti-phosphotyrosine antibodies. 
Figure 6. Inhibition of GPVI-dependent platelet aggregation, GPVI homodimer 
formation and calmodulin dissociation by NADPH oxidase inhibition. (A) Representative 
aggregation traces from human washed platelets treated with CRP in the presence or absence 
of increasing concentrations of the Nox inhibitor, apocynin. Traces are representative of four 
independent experiments using different donors. (B) Immunoblot of washed platelets treated 
with 5 μg/ml CRP in the presence or absence of Nox inhibition (apocynin) following 
preincubation with the metalloproteinase inhibitior, GM6001, to maintain the dimer on the 
platelet surface. Dimer induced by 0.5 μg/ml convulxin (Cvx) is included for comparison. 
Immunoblot was probed with the GPVI monoclonal antibody 4B8. Optical density 
measurements are shown below the corresponding lanes. Data are representative of 3 
  
independent experiments. (C) Washed platelets were treated in the aggregometer with 5 
μg/ml CRP in the presence or absence of redox inhibitors (300 μM apocynin or 10 μM DPI), 
then lysed and immunoprecipitated with an anti-GPVI polyclonal antibody. Immunoblots 
were probed for calmodulin (upper panel) and GPVI (lower panel). Vertical lines represent 
repositioned lanes. (D) Washed platelets were treated in the aggregometer with 5 μg/ml CRP 
for 1 to 3 min, then lysed and immunoprecipitated with an anti-GPVI polyclonal antibody. 
Data are representative of 2 independent experiments. Immunoblots were probed for TRAF4. 
NT, no treatment; PL, platelet lysate; Apo, apocynin; DPI, diphenylene iodonium; Cont, 
irrelevant control antibody. 
Figure 7. Potential role for TRAF4 in the redox-dependence of GPIb and GPVI 
signalling. TRAF4 directly associated with the cytoplasmic tails of GPIbβ/GPVI could 
provide a novel pathway for ligand-induced activation of both Lyn (via Hic-5) and Nox2 (via 
p47phox). Downstream of TRAF4, Lyn-dependent activation of Syk, or p47phox-dependent 
activation of Rac1/2 and Rac/PAK1 together stimulate separate pathways leading to platelet 
integrin activation. Key proteins thus far demonstrated by pull-down and IP/WB to be part of 
the complex with GPIb-IX-V and GPVI are shaded (this study). The association of Syk with 
GPIb and GPVI is published elsewhere [10, 48].   
Supplementary data 
Supplementary Figure 1. Interaction partners of the MBP-GPVI affinity column. 2 μl of 
each flow-through or guanidine-HCl eluted fraction were blotted onto a nitrocellulose 
membrane and probed for the following proteins: MBP, GPVI, TRAF4, Hic-5, p47phox and 
Fyn. 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
